CN102766701B - The kit of HCV gene typing and method - Google Patents
The kit of HCV gene typing and method Download PDFInfo
- Publication number
- CN102766701B CN102766701B CN201210229235.9A CN201210229235A CN102766701B CN 102766701 B CN102766701 B CN 102766701B CN 201210229235 A CN201210229235 A CN 201210229235A CN 102766701 B CN102766701 B CN 102766701B
- Authority
- CN
- China
- Prior art keywords
- probe
- hcv
- type
- kit
- internal reference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title abstract description 24
- 239000000523 sample Substances 0.000 claims abstract description 96
- 239000012528 membrane Substances 0.000 claims abstract description 27
- 239000004677 Nylon Substances 0.000 claims abstract description 17
- 229920001778 nylon Polymers 0.000 claims abstract description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 26
- 229960002685 biotin Drugs 0.000 claims description 13
- 235000020958 biotin Nutrition 0.000 claims description 13
- 239000011616 biotin Substances 0.000 claims description 13
- 238000002372 labelling Methods 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 3
- 241000219194 Arabidopsis Species 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 238000009396 hybridization Methods 0.000 abstract description 15
- 238000001514 detection method Methods 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000002068 genetic effect Effects 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000009434 installation Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to a kind of disease pathogen technique of gene detection, relate in particular to a kind of kit and method of HCV gene typing, can be used for the type 1a of the HCV that detects domestic generation, 1b, 2a, 2b, 3a, the auxiliary diagnosis that 6a infects. The present invention adopts nylon membrane carrier, for HCV different genotype design oligonucleotides probe, is prepared into genetic chip, then is equipped with PCR primer and other components, can quick and precisely carry out somatotype to HCV in blood sample. The genetic chip of HCV gene typing of the present invention and kit and method have quick, sensitive, accurate, high-throughout feature, one time hybridization reaction can detect multiple target sequence, draw materials conveniently, without special installation, instrument drop into low, have fast and convenient, susceptibility is high and the feature of high specificity.
Description
Technical field
The present invention relates to a kind of disease pathogen technique of gene detection, relate in particular to a kind of HCV gene typingKit and method, for detection of the type 1a of the HCV of domestic generation, 1b, 2a, 2b, 3a, it is auxiliary that 6a infectsHelp diagnosis.
Background technology
HCV (hepatitisCvirus, HCV), hepatitis C is worldwide distribution, and crowd is generally easySense is serious harm human health, Epidemic Scope infectious disease widely. Its pathogen is HCV (hepatitisCVirus, HCV). At present, its infection rate is 0.1%-10%, average out to 3%. The whole world has and exceedes 1.7 hundred million people's HCV infection, whereinHave every year to exceed 100,000 routine HCV patients and develop into liver cancer, and then occur hemorrhage of digestive tract and ascites. According to WHO2002Report, in calendar year 2001, chronic liver disease causes that 1,400 ten thousand examples are dead, comprise 79.6 ten thousand examples by cirrhosis cause, 61.6 ten thousand examples are by formerProperty liver cancer causes.
HCV is positivity single stranded RNA flavivirus, comprises a 9400 left and right nucleotides. HCV genome has independent openingPut reading frame, gene structure is made up of 5 '-NCR-C-E1-E2-NS1-NS2-NS3-NS4-NS5-N-CR-3 ', and coding one has3010 amino acid whose polyprotein bodies, are divided into virus replication and virion and form necessary structure and non-structure after translationAlbumen. HCV has variability highly, and (its aberration rate is up to 1.4-1.9 × 10-3/ nucleotides/year) and itself there is negative selectionThe feature of effect, high sudden change is because replicase is without calibration function; Easily mistake property RDRP (error-proneRDRP, EP-RDRP)Existence and the reason such as selection effect just. Show as and itself there is negative selection effect: various bases in viral genomeBecause of structure and function difference, some region height is conservative. The not whole or portion of homophyletic of HCV separating according to different regions, the whole worldDivide genomic phylogenetic analysis, HCV is divided into 6 kinds of main genotype (representing with 1-6), and the various hypotype of dividing is again (with a, b, cDeng expression). HCV hypotype has exceeded 100, and wherein modal is 1a, 1b, and 2a, 2b, 3a, 6a, between various nucleotide sequenceDiffer 31-34%, it is about 30% that amino acid sequence differs, and between hypotype sequence, differ about 20-23%. There are several HCV diseasesStrain is mainly separated from Southeast Asia, is named as HCV7, and 8,9,10,11 types, except HCV10a type (is put at presentHCV3 type), due to the similitude on its phyletic evolution, all the other various HCV6 types that are put into.
Research shows, between the different types of HCV, the susceptibility of interferon therapy is differed, and particularly 1 type is compared with other typeSusceptibility is particularly poor. The infectious hepatitis of different type HCV, the moderate that it is acute, chronic and severe, posthepatitic cirrhosis and formerProperty liver cancer incidence has difference, and the clinical state of an illness of HCV genotype and hepatitis C patients and the order of severity thereof are closely related. In view ofDifferent HCV genotype the infecteds' clinical manifestation, the hepatopathy order of severity and chronicity course advancement are all variant, antiviral therapyEffect also different. Therefore detect complexity, formulation individuation antiviral therapy side that HCV genotype contributes to judgement treatmentCase.
At present HCV methods of genotyping is mainly contained: restricted length polymorphism analysis method (RFLP), Serotype-dependentPrimer PCR method, Serotype-dependent probe nucleic acid hybridization analysis method, the methods such as direct sequencing, but these methods are deposited mostlyThe shortcomings such as at complex operation, high to equipment requirement, detection time is long, and flux is low, also exists sensitivity low, and specificity is not high.
Summary of the invention
The object of the invention is to overcome defect and the deficiency of prior art, manufacture third type with high flux, high accuracyThe genetic chip of virogene of hepatitis somatotype and kit and method, can disposablely accurately divide HCV in multiple samplesType detects, and saves detection time.
Technical solution of the present invention, for a kind of kit of HCV gene typing is provided, mainly comprises PCR reactionLiquid and DNA hybond membrane bar, described DNA hybond membrane bar comprises nylon membrane, on described nylon membrane, is fixed with probe, described probe is canWith the nucleotides of the nucleic acid hybridization of the various subtype virus of HCV, described probe sequence is as follows respectively:
For HCV1a type designing probe Y1:5 '-AATTGCCAGGACGACCGG-3 ';
For HCV1b type designing probe Y2:5 '-AATTGCCAGGATGACCGGG-3 ';
For HCV1b type designing probe Y3:5 '-CCCGGAATTGCCAGGAC-3 ';
For HCV2a type designing probe Y4:5 '-CAATGCCTGGAGATTTGGGCG-3 ';
For HCV2a type designing probe Y5:5 '-CAATGCCTGGAGATTTGGGC-3 ';
For HCV2b type designing probe Y6:5 '-CTCAATGCCTGGAGATTTGG-3 ';
For HCV2b type designing probe Y7:5 '-GCTCAATGCCTGGAGATTTGG-3 ';
For HCV3a type designing probe Y8:5 '-CAATGCCTGGAGATTTGGG-3 ';
For HCV3a type designing probe Y9:5 '-CGAGGTAGACGTCAGCC-3 ';
For HCV3a type designing probe Y10:5 '-ACCTCGAGGTAGACGTCAGCC-3 ';
For HCV6a type designing probe Y11:5 '-AACCTCGAGGTAGACGTCAGCC-3 ';
For HCV6a type designing probe Y12:5 '-GCAACCTCGAGGTAGACGT-3 ';
For HCV6a type designing probe Y13:5 '-TAGACGTCAGCCTATCCCCAA-3 ';
For HCV1-6 type design general probe (being positive probe HP) Y14:5 '-TAGACGCCAGCCTATTCCCA-3 ';
Negative probe HN:5 '-GGTCCTGTTTAACTGGCG-3 ';
Described each probe 5 ' end carry out amino labeled with nylon membrane coupling.
Preferably, in the kit of above-mentioned HCV gene typing, on described nylon membrane, be also provided with colour developing controlManufacturing probe CC, described colour developing control probe CC sequence is as follows: 5 '-GCGCAGGGCCACAATAATGG-3 ', described cc probe5 ' end carries out amino labeled, and 3 ' end carries out biotin labeling.
Preferably, in the kit of above-mentioned HCV gene typing, described PCR reactant liquor comprises amplification the third type liverThe primer of the nucleic acid of scorching viral various subtype virus, described primer sequence is as follows:
Reverse transcriptase primer RT:5 '-CGTCTAGCCATGGCGTTAGT-3 ';
Upstream primer F:5 '-GAAAGCGTCTAGCCATGGCGTTAGT-3 ';
Downstream primer R:5 '-CGCAAGCACCCTATCAGGCAGTA-3 '.
5 ' the end of described upstream primer F carries out biotin labeling.
Preferably, in the kit of above-mentioned HCV gene typing, described PCR reactant liquor also comprises internal reference systemSystem, described internal reference system is arabidopsis internal reference system, comprising:
Internal reference primers F 1:5 '-TCATCGTCGCTGGAGCTGGTT-3 ';
Internal reference primer R1:5 '-CGGCGGTTTGTCAAGCTGAT-3 ';
Internal reference probe PC:5 '-TGCCGATATAGGTCACAGCATGGGC-3 ';
5 ' end of described internal reference primers F 1 carries out biotin labeling.
Preferably, in the kit of above-mentioned HCV gene typing, described concentration and probe concentration is 5-20 μ M.
Another technical scheme of the present invention is for providing a kind of method of HCV gene typing, and the method comprisesFollowing concrete steps:
A, design serotype specific primer and probe, described probe is as shown in claim 1 probe Y1-Y14, and described primer comprises contraryTranscribe primer RT:5 '-CGTCTAGCCATGGCGTTAGT-3 ';
Upstream primer F:5 '-GAAAGCGTCTAGCCATGGCGTTAGT-3 ';
Downstream primer R:5 '-CGCAAGCACCCTATCAGGCAGTA-3 ';
5 ' end of probe described in b, use active amino markers step a, and it is fixed on nylon membrane successively, detection madeFilm bar, carries out biotin labeling to the 5 ' end of described downstream primer R;
C, utilize primer described in step a to carry out HCVDNA amplification, by amplified production with detect the hybridization of film bar, with peroxideCompound enzyme and tetramethyl benzidine colour developing;
D, employing scanner, scanning hybridization signal, judges Genotyping result.
Preferably, the method for above-mentioned HCV gene typing, is also provided with colour developing and controls on described nylon membraneProbe CC, described colour developing control probe CC sequence is as follows: 5 '-GCGCAGGGCCACAATAATGG-3 ', described colour developing control5 ' the end of probe CC carries out amino labeled, and 3 ' end carries out biotin labeling.
Preferably, the method for above-mentioned HCV gene typing, the primer in described step a also comprises:
Internal reference primers F 1:5 '-TCATCGTCGCTGGAGCTGGTT-3 ';
Internal reference primer R1:5 '-CGGCGGTTTGTCAAGCTGAT-3 ';
Probe in described step a also comprises:
Internal reference probe PC:5 '-TGCCGATATAGGTCACAGCATGGGC-3 ';
5 ' end of described internal reference primers F 1 carries out biotin labeling.
The genetic chip of HCV gene typing of the present invention and kit and method have quick, sensitive, accurateReally, high-throughout feature, one time hybridization reaction can detect multiple target sequence, draws materials conveniently, without special installation, instrument drops intoLow, have fast and convenient, susceptibility is high and the feature of high specificity.
Brief description of the drawings
Fig. 1: the arrangement schematic diagram of HCV probe of the present invention on nylon membrane;
Fig. 2: 1 type HCV Virus Sample testing result scintigram;
Fig. 3: 2 type HCV Virus Sample testing result scintigrams;
Fig. 4: 3 type HCV Virus Sample testing result scintigrams;
Fig. 5: 6 type HCV Virus Sample testing result scintigrams.
Detailed description of the invention
By describing technology contents of the present invention, structural feature in detail, being realized object and effect, below in conjunction with embodimentAnd coordinate accompanying drawing to be explained in detail.
The object of the invention is to prepare a kind of HCV (HCV) gene typing DNA hybond membrane bar, a large amount of to meetBlood sample carries out the quick and precisely needs of somatotype of HCV.
For this reason, the present invention by the following technical solutions: adopt reversal point hybridization technique (ReverseDotBlot, RDB),With nylon membrane, as solid phase carrier, the specific oligonucleotide probe designing for HCV different genotype, by each HCV specificityProbe is fixed on film bar in the mode of round dot, is prepared into DNA hybond membrane bar, and with biotin labeling primer, sample to be checked increasesObject nucleic acid fragment, obtain with biotin labeled amplified production; Assorted with the film bar of fixing various oligonucleotide probes againHand over, by integrated enzyme reaction and colour developing, after scanning, with professional spot-analysis software, image is identified, removed background, carries outObjectively signal value analysis, thus judge in amplified production whether have the gene order for various oligonucleotide probes, at knotIn fruit judgement, reduce the subjective factors of artificial identification, be more suitable for Clinical detection application.
The present invention is directed to other gene order of HCV different shaped, design a set of specific oligonucleotide probe (as shown in table 1For sequence oligonucleotide probe and the type that detects), adopt automatic point sample instrument, probe is printed on to the spy of a nylon membraneDetermine region, judge the type of HCV according to the difference in colour developing site.
On the basis of above-mentioned DNA hybond membrane bar, be equipped with again other necessary component, as PCR primer (is as shown in table 2lyThe primer sequence that the present invention is used), form complete product. In the time that reality detects, get the HCV sample of nucleic acid solution of extraction,Adopt biotin labeling primer and asymmetric PCR method, amplify the HCV genome biotin labeling target sheet that may existSection. Get one of DNA hybond membrane bar, add PCR product 45 μ L to hybridize, hybridization temperature is set as 45 DEG C, 60 points of hybridization timeClock, through hybridization-washing-colour developing. Take out film bar and dry, put into scanner and scan, use analysis software to scan imageSignal carries out view data conversion process, and analyzes generation sample HCV type result.
According to another preferred embodiment of the present invention, introducing interior reference for the PCR system of sample amplificationThing, and internal reference template, and time prepared by film bar, introduced the probe that can hybridize with internal reference template, can be to PCR processCarry out effective mass control.
According to another preferred embodiment of the present invention, in the time preparing film bar, introduce colour developing and controlled probe (CC.),At one end of probe mark-NH2, with nylon membrane coupling, the other end is introduced biotin labeling, can directly develop the color. CCIntroducing can carry out effective mass control to process color.
Another preferred embodiment according to the present invention, the sheet base carrier of DNA hybond membrane bar can be slide, nylon membraneOr other can adhesion probe carrier.
Table 1
Table 2
Embodiment
1,5 ' UTR district design RT and PCR primer in HCV genome, adopts asymmetric RT-PCR system, amplification somatotype instituteThe target fragment needing; As shown in table 1, within the scope of target fragment, 3 of design 1 type probes, 24 of type probes, 3 type probes 3Bar, 1 of 6 three of type probes and general probe.
2, refer to Fig. 1 by nylon membrane by the format print grid designing, adopt automatically some film instrument, 14 somatotypes are visitedPin and 2 contrast probe points system, to the specific region of film bar, is made DNA hybond membrane bar.
Point sample probe solution: by probe dilution to 5 × SSC, 0.05%SDS solution, final concentration is 10 μ M;
Point sample matrix: by probe points on film bar, each probe point sample 0.5pM, every row 8 points, totally 2 row (referring to Fig. 1).
3, use product of the present invention to detect clinical sample
Get various other clinical sample 6 examples and positive and negative and contrast each portion, extract RNA, prepare RT-PCR according to table 3 anti-Answer system, each primer is as shown in table 3, carries out pcr amplification, obtains DNA hybridization template.
Table 3
| Reagent | 1 person-portion (μ L) |
| Pure water | 21.5 |
| 10×PCR buffer | 5 |
| 25mM MgCl2 | 6 |
| dNTP(10mM) | 1 |
| 10μM F | 2 |
| 10μM R | 1 |
| 10μM F1 | 2 |
| 10μM R1 | 1 |
| Reverse transcriptase/Taq enzyme | 0.5 |
| RNA template | 10 |
| Total amount | 50 |
Pcr amplification program is as follows:
Adopt HCV Genotyping hybond membrane bar of the present invention, above sample is detected.
Get a hybond membrane bar, marker samples numbering, puts into hybrid pipe, get respectively the each 45 μ L of 8 pipe PCR product be added to rightIn the pipe that should number, set 45 DEG C of hybridization temperatures, hybridization time 60 minutes. After hybridization, wash, coupling, colour developing and air-dry.Concrete operations are as follows:
1) hybridization:
Get 15mL centrifuge tube, put into 1 of label film bar, add 5-8ml preheating A liquid (2*SSC, 0.5%SDS), corresponding40ulPCR product, covers tightly pipe lid, puts into vibration tank, 50 DEG C of jogs (100～150 revs/min), 40 minutes. Discard liquid.
2) coupling: (at every turn can simultaneously process 5 film bars)
Get 50mL centrifuge tube, preheating B liquid (0.5*SSC, 0.5%SDS) 20ml, C liquid (0.01%TMB) 1ml, mixes, and putsEnter hybond membrane bar, 50 DEG C of jogs (40～50 revs/min) 10 minutes, discard liquid;
Add preheating B liquid (0.5*SSC, 0.5%SDS) 40ml, 50 DEG C of jogs 3 minutes, discard liquid; Add D liquid (0.5M lemonAcid sodium, pH5.5) 40ml, 50 DEG C of jogs 3 minutes, discard liquid.
3) colour developing: (can process 5-10 at every turn simultaneously and open film bar)
Get 50mL centrifuge tube, add D liquid (0.5M natrium citricum, pH5.5) 20ml, E liquid 1ml (0.025%POD), F liquid(0.3H2O2) 1ml, mix and be nitrite ion, put into film bar and leave standstill 8 minutes in room temperature lucifuge, discard liquid;
Add D liquid (0.5M natrium citricum, pH5.5) 40ml, jog 3 minutes, discards liquid. Hybridization completes.
Adopt scanner, scanning hybridization signal, obtains results of hybridization scintigram (seeing Fig. 2-Fig. 5), and image is converted toData.
Adopt analysis software, above data analysis is converted into the gene type of each sample, meanwhile, by 8 partsSample DNA order-checking, contrasts as testing result. Result shows, 8 these testing results of increment conform to completely with sample sequencing result(in table 4).
Embodiment has illustrated the advantage of product of the present invention aspect detection flux, once can make the sample of arbitrary number; InspectionSurvey the reliability (testing result conforms to completely with sample sequencing result) of accuracy aspect.
Table 4
| Sample number | Sequencing result | This result of the test | Whether conform to |
| 01 | 1 type | 1 type | Be |
| 02 | 2 types | 2 types | Be |
| 03 | 1 type | 1 type | Be |
| 04 | 3 types | 3 types | Be |
| 05 | 3 types | 3 types | Be |
| 06 | 6 types | 6 types | Be |
| 07 | 1 type | 1 type | Be |
| 08 | 6 types | 6 types | Be |
The foregoing is only embodiments of the invention, not thereby limit the scope of the claims of the present invention, everyly utilize thisThe equivalent structure that bright description and accompanying drawing content are done or the conversion of equivalent flow process, or be directly or indirectly used in other relevant skillsArt field, is all in like manner included in scope of patent protection of the present invention.
Claims (4)
1. the kit of HCV gene typing, mainly comprises PCR reactant liquor and DNA hybond membrane bar, it is characterized in that,Described DNA hybond membrane bar comprises nylon membrane, on described nylon membrane, is fixed with probe, and described probe is can be respectively and hepatitis C virusThe nucleotides of the nucleic acid hybridization of the various subtype virus of poison, described probe sequence is as follows:
For HCV1a type designing probe Y1:5 '-AATTGCCAGGACGACCGG-3 ';
For HCV1b type designing probe Y2:5 '-AATTGCCAGGATGACCGGG-3 ';
For HCV1b type designing probe Y3:5 '-CCCGGAATTGCCAGGAC-3 ';
For HCV2a type designing probe Y4:5 '-CAATGCCTGGAGATTTGGGCG-3 ';
For HCV2a type designing probe Y5:5 '-CAATGCCTGGAGATTTGGGC-3 ';
For HCV2b type designing probe Y6:5 '-CTCAATGCCTGGAGATTTGG-3 ';
For HCV2b type designing probe Y7:5 '-GCTCAATGCCTGGAGATTTGG-3 ';
For HCV3a type designing probe Y8:5 '-CAATGCCTGGAGATTTGGG-3 ';
For HCV3a type designing probe Y9:5 '-CGAGGTAGACGTCAGCC-3 ';
For HCV3a type designing probe Y10:5 '-ACCTCGAGGTAGACGTCAGCC-3 ';
For HCV6a type designing probe Y11:5 '-AACCTCGAGGTAGACGTCAGCC-3 ';
For HCV6a type designing probe Y12:5 '-GCAACCTCGAGGTAGACGT-3 ';
For HCV6a type designing probe Y13:5 '-TAGACGTCAGCCTATCCCCAA-3 ';
For HCV1-6 type design general probe Y14:5 '-TAGACGCCAGCCTATTCCCA-3 ';
Negative probe HN:5 '-GGTCCTGTTTAACTGGCG-3 ';
Described each probe 5 ' end carry out amino labeled with nylon membrane coupling.
2. the kit of HCV gene typing as claimed in claim 1, is characterized in that, on described nylon membrane, goes backBe provided with colour developing and control probe CC, described colour developing control probe CC sequence is as follows: 5 '-GCGCAGGGCCACAATAATGG-3 ', the 5 ' end of described colour developing control probe CC carries out amino labeled, and 3 ' end carries out biotin labeling.
3. the kit of HCV gene typing as claimed in claim 1, is characterized in that, described PCR reactant liquorAlso comprise internal reference system, described internal reference system is arabidopsis internal reference system, comprising:
Internal reference primers F 1:5 '-TCATCGTCGCTGGAGCTGGTT-3 ';
Internal reference primer R1:5 '-CGGCGGTTTGTCAAGCTGAT-3 ';
Internal reference probe PC:5 '-TGCCGATATAGGTCACAGCATGGGC-3 ';
5 ' end of described internal reference primers F 1 carries out biotin labeling.
4. the kit of HCV gene typing as claimed in claim 1, is characterized in that, described concentration and probe concentration is5-20μM。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210229235.9A CN102766701B (en) | 2012-07-04 | 2012-07-04 | The kit of HCV gene typing and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210229235.9A CN102766701B (en) | 2012-07-04 | 2012-07-04 | The kit of HCV gene typing and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102766701A CN102766701A (en) | 2012-11-07 |
| CN102766701B true CN102766701B (en) | 2016-05-04 |
Family
ID=47094267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210229235.9A Active CN102766701B (en) | 2012-07-04 | 2012-07-04 | The kit of HCV gene typing and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102766701B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103710464B (en) * | 2013-12-30 | 2015-03-11 | 湖南圣维尔医学检验所有限公司 | HCV (Hepatitis c virus) genotype detection kit |
| CN103966363B (en) * | 2014-05-16 | 2016-05-04 | 福州泰普生物科学有限公司 | A kind of kit of HCV gene typing |
| CN104131087B (en) * | 2014-07-11 | 2016-01-27 | 武汉千麦医学检验所有限公司 | A kind of test kit carrying out gene type for folic acid metabolism gene |
| CN104152570B (en) * | 2014-08-25 | 2016-09-14 | 武汉千麦医学检验所有限公司 | A kind of basal cell cancer susceptibility gene SNP polymorphic detection test kit |
| CN104357584A (en) * | 2014-11-04 | 2015-02-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Preparation and application of guiding gene chip for HCV infection individual treatment |
| CN109593887B (en) * | 2018-12-29 | 2022-10-11 | 广州达安基因股份有限公司 | Kit for quantitative detection of hepatitis C virus nucleic acid |
| CN115261518B (en) * | 2022-08-26 | 2023-06-06 | 北京爱普益生物科技有限公司 | Primer combination, kit and application of hepatitis C virus genotyping |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996013590A2 (en) * | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| CN1167812C (en) * | 2000-07-23 | 2004-09-22 | 浙江江南生物科技有限公司 | Biochip for typing non-coding region gene of hepatitis C virus HCV5' |
| CN1262672C (en) * | 2001-04-12 | 2006-07-05 | 株式会社生物核心 | Oligonucleotides chip composition for analyzing HCV gene type and its detecting method |
| US20070072211A1 (en) * | 2005-06-30 | 2007-03-29 | Roche Molecular Systems, Inc. | Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids |
-
2012
- 2012-07-04 CN CN201210229235.9A patent/CN102766701B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| GenBank: HQ113670.1;Li,H. et al.;《Genbank》;20110717;1-2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102766701A (en) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102766701B (en) | The kit of HCV gene typing and method | |
| Cai et al. | Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay | |
| Olive et al. | Detection and differentiation of picornaviruses in clinical samples following genomic amplification | |
| CN107513584B (en) | A kind of five heavy fluorescence quantitative kits detecting enterovirus | |
| CN101392302B (en) | Flu/human avian influenza virus detection gene chip and production method and use | |
| CN110699489B (en) | Real-time fluorescence PCR detection primer probe set, kit and method for African swine fever virus CD2V gene | |
| IL189281A (en) | In vitro diagnostic method and kit for identification of human papillomavirus in clinical samples | |
| CN106755535A (en) | Primer, probe, kit and method for detecting mankind's CYP2C19 gene pleiomorphisms | |
| CN105296673A (en) | Influenza A virus molecular detection kit and preparation method thereof | |
| CN100460519C (en) | Reagent box for detecting prawn infectious subcutaneous and hemopoietic tissue necrosis virus and method thereof | |
| CN103966363B (en) | A kind of kit of HCV gene typing | |
| Rashid et al. | Multiplex polymerase chain reaction for the detection and differentiation of avian influenza viruses and other poultry respiratory pathogens | |
| CN102586473A (en) | Hepatitis B virus genotyping PCR (polymerase chain reaction) test kit | |
| CN105063760A (en) | Gene chip for identification of seven swine disease pathogens and detection method thereof | |
| CN107523649A (en) | H7N9 subtype influenza virus genome sequencing methods | |
| CN104232800A (en) | Gene chip and kit for detecting porcine japanese encephalitis virus, swine fever virus and porcine reproductive and respiratory syndrome virus | |
| CN105112558B (en) | The triple real time fluorescent quantitative RT PCR detection kits of the type of foot and mouth disease virus O, A and Asia I | |
| CN104357584A (en) | Preparation and application of guiding gene chip for HCV infection individual treatment | |
| CN104293981A (en) | Gene chip and kit for detecting swine epidemic encephalitis B viruses (SEEBVs) and/or swine fever viruses (SFVs) | |
| CN104293976A (en) | Gene chip and kit for detecting pig epidemic type B encephalitis virus and/or pig porcine reproductive and respiratory syndrome virus | |
| CN115323075B (en) | RT-RAA primer probe group and kit for detecting infectious bronchitis viruses and genotyping and application of RT-RAA primer probe group and kit | |
| CN105296675A (en) | Nucleic acid detecting kit for influenza B viruses and preparation method of nucleic acid detecting kit | |
| CN109517929B (en) | Primer group and kit for porcine circovirus detection and type2 typing | |
| CN101235414B (en) | Subtype detection method and reagent kit for hepatitis B virogene | |
| CN107267666A (en) | A kind of fluorescent quantitation RT PCR detection kits based on pig atypia pestivirus raq gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20220411 Granted publication date: 20160504 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20240123 Granted publication date: 20160504 |